ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,162.80
0.60%
Dow Jones
38,085.80
-0.98%
Brent Oil
88.285
0.15%
Bitcoin
64,483.81
0.00%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) Quote

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.31
0.02
(1.55%)
Closed April 26 4:00PM
Delayed by 15 minutes
1.31
0.00
(0.00%)
After Hours: 5:16PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.31
Bid
1.26
Ask
1.40
Volume
138,210
1.28 Day's Range 1.36
1.02 52 Week Range 7.64
Market Cap
63.218M
Previous Close
1.29
Open
1.28
Last Trade
1
@
1.35
Last Trade Time
Financial Volume
$ 178,733
VWAP
1.2932
Average Volume (3m)
418,145
Shares Outstanding
48,258,111
Dividend Yield
-
PE Ratio
-0.93
Earnings Per Share (EPS)
-1.41
Revenue
9.16M
Net Profit
-68.17M

About Ikena Oncology Inc

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.ikenaoncology.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was $1.29. Over the last year, Ikena Oncology shares have traded in a share price range of $ 1.02 to $ 7.64.

Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is $63.22 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -0.93.

IKNA Latest News

More News

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

April 10 2024
GlobeNewswire Inc.

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients...

March 12 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

February 27 2024
GlobeNewswire Inc.

Form 8-K - Current report

February 21 2024
Edgar (US Regulatory)

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development...

February 21 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

February 02 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.075.645161290321.241.421.222351721.3121547CS
4-0.09-6.428571428571.41.461.222352451.32443704CS
12-0.05-3.676470588241.361.651.224181451.42937695CS
26-2.15-62.13872832373.464.6251.023235201.52413703CS
52-3.6-73.31975560084.917.641.022135792.50385069CS
156-19.72-93.770803613921.0326.48991.021604255.82217233CS
260-21.09-94.151785714322.437.611.021662056.76197842CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ISUNiSun Inc
$ 0.173
(84.04%)
19.93M
BRFHBarfresh Food Group Inc
$ 1.75
(69.90%)
44.33M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
136.91M
PCSAProcessa Pharmaceuticals Inc
$ 2.4137
(48.99%)
77.21M
BACKIMAC Holdings Inc
$ 5.065
(45.34%)
8.49M
EJHE Home Household Service Holdings Ltd
$ 0.767
(-73.64%)
12.24M
TVGNTevogen Bio Holdings Inc
$ 0.9057
(-39.62%)
328.55k
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.265
(-37.69%)
15.53M
ATNIATN International Inc
$ 19.24
(-33.01%)
440k
BNAIBrand Engagement Network Inc
$ 2.59
(-30.56%)
234.29k
SQQQProShares UltraPro Short QQQ
$ 12.00
(1.61%)
159.11M
SGBXSafe and Green Holdings Corporation
$ 0.225
(56.14%)
132.51M
TSLATesla Inc
$ 170.18
(4.97%)
120.89M
ACONAclarion Inc
$ 0.383149
(33.04%)
115.37M
PEGYPineapple Energy Inc
$ 0.0517
(0.78%)
82.42M

IKNA Discussion

View Posts
Monksdream Monksdream 1 month ago
IKNA under $2=
👍️0
Monksdream Monksdream 2 months ago
IKNA under $2
👍️0
herbied47 herbied47 6 months ago
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 6 months ago
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 6 months ago
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 6 months ago
what happened here my short friend
👍️0
Tacostocks Tacostocks 6 months ago
Aged like milk eh
👍️0
AJ Freely AJ Freely 9 months ago
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 1 year ago
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 2 years ago
IKNA monster
👍️0
crudeoil24 crudeoil24 3 years ago
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

Your Recent History

NASDAQ
IKNA
Ikena Oncology
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved